HR 6092 RFS
(6) For veterans with prostate cancer, including 
prostate cancer that has metastasized, precision on-
cology, including biomarker-driven clinical trials and 
innovations underway through the Prostate Cancer 
Foundation and Department of Veterans Affairs 
partnership, represents one of the most promising 
areas of interventions, treatments, and cures for 
such veterans and their families. 
SEC. 3. DEPARTMENT OF VETERANS AFFAIRS TREATMENT 
AND RESEARCH OF PROSTATE CANCER. 
(a) ESTABLISHMENT OF CLINICAL PATHWAY.— 
(1) IN
GENERAL.—Not later than 365 days 
after the date of the enactment of this Act, the Sec-
retary of Veterans Affairs shall establish in the Na-
tional Surgery Office of the Department of Veterans 
Affairs a national clinical pathway for all stages of 
prostate cancer, from early detection to end-of-life 
care including recommendations regarding the use of 
transformative innovations, research, and uniform 
clinical data. 
(2) ELEMENTS.—The national clinical pathway 
established under this subsection shall include the 
following elements: 
(A) A multi-disciplinary plan for the early 
detection, diagnosis, and treatment of prostate 
VerDate Sep 11 2014 
18:09 Sep 24, 2020
Jkt 099200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H6092.RFS
H6092
pamtmann on DSKBC07HB2PROD with BILLS
HR 6092 RFS
cancer that includes, as appropriate, both De-
partment medical facilities and community- 
based partners and providers and research cen-
ters specializing in prostate cancer, especially 
such centers that have entered into partner-
ships with the Department. 
(B) A suggested, but not mandatory, pro-
tocol for screening, diagnosis, and treatment or 
care for subpopulations with evidence-based risk 
factors (including race, ethnicity, socioeconomic 
status, geographic location, exposure risks, and 
genetic risks, including family history). 
(C) A suggested treatment protocol time-
frame for each point of care based on severity 
and stage of cancer. 
(3) PUBLIC COMMENT PERIOD.—Upon the es-
tablishment of a proposed clinical pathway as re-
quired under this subsection, the Secretary shall 
publish the proposed clinical pathway in the Federal 
Register and provide for a 45-day period for public 
comments. The Secretary— 
(A) may make any such public comments 
publicly available; and 
(B) make changes to the proposed clinical 
pathway in response to any such comments re-
VerDate Sep 11 2014 
18:09 Sep 24, 2020
Jkt 099200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H6092.RFS
H6092
pamtmann on DSKBC07HB2PROD with BILLS
HR 6092 RFS
ceived using the same process and criteria used 
to establish the proposed clinical pathway. 
(4) COLLABORATION AND COORDINATION.—In 
establishing the clinical pathway required under this 
section, the Secretary shall— 
(A) provide for consideration of other clin-
ical pathways and research findings of other de-
partments and agencies, including guidelines 
that are widely recognized and guidelines that 
are used as the standard for clinical policy in 
oncology care, such as National Comprehensive 
Cancer Network guidelines; and 
(B) collaborate and coordinate with— 
(i) the National Institutes of Health; 
(ii) the National Cancer Institute; 
(iii) the National Institute on Minor-
ity Health and Health Disparities; 
(iv) other Institutes and Centers as 
the Secretary determines necessary; 
(v) the Centers for Disease Control 
and Prevention; 
(vi) the Department of Defense; 
(vii) the Centers for Medicare and 
Medicaid Services; 
VerDate Sep 11 2014 
18:09 Sep 24, 2020
Jkt 099200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H6092.RFS
H6092
pamtmann on DSKBC07HB2PROD with BILLS
HR 6092 RFS
(viii) the Patient-Centered Outcomes 
Research Institute; and 
(ix) the Food and Drug Administra-
tion. 
(5) PUBLICATION.—The Secretary shall— 
(A) publish the clinical pathway estab-
lished under this subsection on a publicly avail-
able Department website; and 
(B) regularly update the clinical pathway 
as needed by review of the medical literature 
and available evidence-based guidelines at least 
annually, in accordance with the criteria under 
paragraph (2). 
(b) DEVELOPMENT OF NATIONAL CANCER OF THE 
PROSTATE
CLINICAL
CARE
IMPLEMENTATION
PRO-
GRAM.— 
(1) ESTABLISHMENT.—Not later than 90 days 
after the date of the enactment of this Act, the Sec-
retary shall submit to Congress a plan to establish 
a comprehensive prostate cancer program. 
(2) PROGRAM
REQUIREMENTS.—The compre-
hensive prostate cancer program shall— 
(A) be multidisciplinary and include the 
authority to work across clinical care lines, spe-
VerDate Sep 11 2014 
18:09 Sep 24, 2020
Jkt 099200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H6092.RFS
H6092
pamtmann on DSKBC07HB2PROD with BILLS
HR 6092 RFS
cialties, and the organizational divisions of the 
Veterans Health Administration; 
(B) receive direct oversight from the Dep-
uty Undersecretary for Health of the Depart-
ment of Veterans Affairs; 
(C) include a yearly program implementa-
tion evaluation to facilitate replication for other 
disease states or in other healthcare institu-
tions; 
(D) be metric driven and include the devel-
opment of quarterly reports on the quality of 
prostate cancer care, which shall be provided to 
the leadership of the Department, medical cen-
ters, and providers and made publicly available 
in an electronic form; 
(E) made available as national decision 
support tools in the electronic medical record; 
and 
(F) include an education plan for patients 
and providers. 
(3) 
PROGRAM
IMPLEMENTATION
EVALUA-
TION.—The Secretary shall establish a program 
evaluation tool as an integral component to learn 
best practices of multidisciplinary disease-based im-
plementation and to inform the Department and 
VerDate Sep 11 2014 
18:09 Sep 24, 2020
Jkt 099200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H6092.RFS
H6092
pamtmann on DSKBC07HB2PROD with BILLS